Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials

BMC Musculoskeletal Disorders

Madelaine M Wohlreich¹  Jonna Ahl¹  Dustin Ruff¹  Joseph L Micca² 

[1] Lilly USA, LLC, Drop Code 4133, Indianapolis, IN, 46285, USA;Patient Centered Healthcare, Atlanta, GA, USA

关键词: Pain;    Older patients;    Osteoarthritis of the knee;    Duloxetine;   

Others  :  1132785
DOI  :  10.1186/1471-2474-14-137

 received in 2012-11-28, accepted in 2013-04-12,  发布年份 2013

【 摘 要 】

Background

Osteoarthritis (OA) knee pain is common in older patients and contributes to decreased quality of life. Older patients are generally at higher risk of adverse drug reactions due to age-related changes in physiology that affect drug disposition, metabolism, and response. These analyses examined efficacy and safety outcomes of older (≥65 years) versus younger patients from clinical trials of duloxetine in the management of OA knee pain.

Methods

This is a post hoc analysis of two 13-week studies, in which patients were randomized to duloxetine 60 mg/day or placebo. Both studies allowed potential dose changes after 7 weeks of dosing, with Study I re-randomizing duloxetine treated patients to either stay on 60 mg/day or increase to 120 mg/day; while Study II more closely mimicked clinical practice by escalating only non-responding patients to 120 mg/day. For all analyses patients were subgrouped by age: older (≥65 years) and younger (40–64 years). Overall efficacy and safety age-group comparisons of duloxetine versus placebo were performed using pooled data from both studies with all duloxetine dose levels combined. Safety analyses included discontinuation rates, treatment-emergent adverse events, and serious adverse events. To evaluate the effects of increasing the dose in non-responding patients, only Study II data were evaluated. Treatment arms were defined post hoc as placebo, duloxetine 60 mg/day, and duloxetine 60/120 mg/day.

Results

At study end, patients in each age group who were treated with duloxetine versus placebo had significantly greater improvement in pain (both, p<.05), and there was no significant effect of age on treatment (p=.72). Increasing the dose to 120 mg in non-responding patients was not found to have a significant advantage. Among treatment-emergent adverse events with duloxetine treatment, only dizziness had a significantly differential treatment effect (p=.02) with greater incidence over placebo in younger patients (6.6% versus 0.6%, p=.02), but not in older patients (1.0% versus 3.2%, p=.29).

Conclusions

Duloxetine was efficacious and generally well tolerated for management of symptomatic knee OA in both older and younger patients, but increasing the dose to 120 mg in non-responding patients did not provide additional benefit.

【 授权许可】

   
2013 Micca et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Lawrence RC, Helmick CG, Arnett FC, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer ST, Steen VD, Wolf F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778-799.
• [2]Skevington SM: Investigating the relationship between pain and discomfort and quality of life, using the WHO-QOL. Pain 1998, 76:395-406.
• [3]Axford J, Heron C, Ross F, Victor CR: Management of knee osteoarthritis in primary care: pain and depression are the major obstacles. J Psychosom Res 2008, 64:461-467.
• [4]Bair MJ, Wu J, Damush TM, Sutherland JM, Kroenke K: Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med 2008, 70(8):890-897.
• [5]Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartilage 2008, 16:137-162.
• [6]Fine PG: Pharmacological management of persistent pain in older patients. Clin J Pain 2004, 20:220-226.
• [7]Fitzcharles MA, Lussier D, Shir Y: Management of chronic arthritis pain in the elderly. Drugs Aging 2010, 27:471-490.
• [8]Ickowicz E: Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009, 57:1331-1346.
• [9]Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF: A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005, 6:346-356.
• [10]Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, Raskin J: A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006, 67:1411-1420.
• [11]Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50:2974-2984.
• [12]Russell JI, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM: Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136:432-444.
• [13]Skljarevski V, Ossanna MJ, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S, Detke M, Backonja M: A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009, 16:1041-1048.
• [14]Skljarevski V, Zhang S, Desaiah D, Alaka KJ, Palacios S, Miazgowski T, Patrick K: Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed dose, randomized, double-blind trial. J Pain 2010, 11(12):1282-1290.
• [15]Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC, Bennett RM, Collins H: Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009, 146:253-260.
• [16]Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y, Brown JP: A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment chronic pain due to osteoarthritis of the knee. Pain Pract 2011, 11(1):33-41.
• [17]Abou-Raya S, Abou-Raya A, Helmi M: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Aging 2012, 41(5):646-652.
• [18]Cleeland CS, Ryan KM: Pain assessment: global use of the brief inventory. Ann Acad Med Singapore 1994, 23:129-138.
• [19]Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Herqueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33.
• [20]Wasan AD, Ossanna MJ, Raskin J, Wernicke JF, Robinson MJ, Hall JA, Edwards SE, Lipsius S, Meyers AL, McCarberg BH: Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients. Curr Drug Saf 2009, 4:22-29.
• [21]Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM: Statistics in medicine – reporting of subgroup analyses in clinical trials. N Engl J Med 2007, 357:2189-2194.